On Election Day the stakes are about confidence as much as outcomes. Gabriel Sterling, the Republican chief operating officer in Georgia’s secretary of state office, has spent years defending the mechanics of American elections and warning of the damage done by false fraud claims. Georgia — at the center of 2020 allegations that prompted lawsuits, recounts and a high-profile call from then-President Trump demanding “11,780 votes” — has layered safeguards into its process: pre-election public tests of equipment, universal use of paper ballots that are auditable by hand, routine post-election audits and strict chain-of-custody controls. Sterling says those systems make it “really hard” for tabulation machines to be tampered with, and that nearly all integrity problems traced back to 2020 were investigated and found to be baseless.
Still, millions remain skeptical, Sterling and election experts note, in part because disinformation has been weaponized to raise money and stoke anger. Outside investigators and officials have documented threats and harassment against election workers — including threats that intensified after public accusations — requiring enhanced security for county poll workers, panic buttons, officer escorts and even Narcan on hand after attacks involving fentanyl. Election officials urge voters to look beyond social media gossip: most errors are human mistakes, not fraud, and the decentralized system across nearly 10,000 jurisdictions, combined with verifiable paper ballots and audits, makes it essentially impossible to “steal” a national election. They also caution that closely contested races and vote-counting procedures mean comprehensive results may take days to finalize on election night.
Texas: legal restrictions, medical uncertainty, care deferred
In Texas, successive abortion restrictions have reshaped health care decisions and clinical practice in ways many physicians call dangerous. After the 2021 SB 8 six-week ban with private civil enforcement and a later near-total prohibition except to save the mother’s life, doctors say they face legal ambiguity that chills routine counseling and clinical judgment. Dani Mathisen, then a Texas medical student, learned she was carrying a lethal fetal anomaly and was forced to travel to New Mexico for care because Texas clinicians feared criminal exposure for advising or facilitating a termination — even in the face of clear medical indications. Physicians recount hospitals now involving risk management and attorneys in emergent obstetric decisions; some require legal reviews before offering treatments that formerly would have been routine.
Family physicians and OB‑GYNs in Texas describe diminished training opportunities for residents: restrictions prevent hands-on training for miscarriage care, ectopic pregnancy, pregnancy of unknown location and other complications. As a result, some residents leave for programs in states that still train comprehensively, and applications to Texas OB‑GYN programs have declined. Doctors warn of potential increases in maternal morbidity and mortality; state and federal data suggest maternal deaths rose more in Texas than nationally after restrictions tightened. Hospitals in neighboring states report surges in out‑of‑state patients seeking pregnancy and abortion care, with the University of New Mexico noting large increases in Texas patients. New laws that threaten legal action against those who transport patients out of state and efforts to obtain out‑of‑state medical records add further barriers and fear. Physicians call on lawmakers to work with clinicians to clarify exceptions for emergencies and to restore the ability to provide evidence-based care without fear of prosecution.
The Land of Novo: Ozempic’s ripple effects in Denmark and beyond
A separate story follows Denmark’s transformation as the headquarters of a global pharmaceutical success: Novo Nordisk. Drugs such as Ozempic and Wegovy — GLP-1 receptor agonists originally developed for diabetes and later approved for weight management — have driven explosive demand, lifted Novo Nordisk’s market value and reshaped both the Danish economy and global markets. Lotte Bjerre Knudsen, a Novo scientist who contributed to the GLP‑1 research, reflects on teamwork and the unexpected scale of impact. Novo’s innovations have broadened to treatments with cardiovascular, kidney and liver indications, fueling hiring, pension solvency and economic effects in Denmark where the company now rivals national metrics.
Novo traces its roots to Nobel laureate August Krogh and his wife Marie’s early insulin work and a foundation structure that funnels much of the company’s voting power into philanthropic research. That history helps explain public support in Denmark for a company seen as national and socially minded. CEO Lars Fruergaard Jorgensen emphasizes the company’s values while acknowledging global capitalism’s realities: Novo must compete and price products in markets with complex reimbursement systems. That claim met pushback in U.S. political arenas over pricing and access, and senators pressed the company on affordability. Critics argue the company’s pricing strategy strains systems and patients, while Novo defenders highlight long-term savings from better-managed obesity and diabetes outcomes.
Denmark buzzes with both pride and irony: Novo’s success has generated jobs and housing pressures — former obesity treatment centers have been repurposed to house new employees — and raised debates about societal responses to an obesity epidemic. The company ramps up global manufacturing and investment to meet demand, even as competitors and biosimilars emerge. For Danes who own stock and for policymakers watching health and economic trade‑offs, Novo’s rise illustrates how a pharmaceutical breakthrough can shift industry, national identity and global health conversations.
Taken together, the three stories reflect systems under strain — democratic institutions tested by misinformation, medical practice altered by legal restrictions, and public health and economies reshaped by a pharmaceutical breakthrough. Each segment highlights how policy, science and public trust intersect and how those interactions shape lives, professions and nations.